Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
MIMETAS logo — Human Tissue Models for Better Therapies

MIMETAS

Human Tissue Models for Better Therapies

Founded 2013 The Netherlands The Netherlands 93 employees Grant Total: $31.91M Biotechnology, Health Care +2

General Information

Company Name MIMETAS
Founded Year 2013
Location The Netherlands The Netherlands
Founders / Decision Makers
Team member Team member
Employees 93
Industries Biotechnology, Health Care, Information Technology +1
Funding Stage Grant
Business Model B2B, Platform, DaaS
Revenue Model Service Fee, Product Sales, Project Based
Social

BounceWatch is an independent company data service, not affiliated with MIMETAS. To contact MIMETAS, visit mimetas.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does MIMETAS compare?

A PDF of MIMETAS and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting MIMETAS soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About MIMETAS

MIMETAS, founded in 2013 and headquartered in The Netherlands, operates at the intersection of Biotechnology, Health Care, Information Technology, and VR/AR. The company is renowned for its slogan: Human Tissue Models for Better Therapies. MIMETAS specializes in developing cutting-edge, screenable 3D human disease models that are physiologically relevant. This innovation aids in forging strong drug development partnerships with global pharmaceutical giants, thereby facilitating the creation of groundbreaking therapies aimed at previously untreatable diseases.

The company's commitment to innovation is underscored by its successful acquisition of a €3.01M grant investment from the EASME - EU Executive Agency for SMEs as of 01 January 2019. This investment not only highlights investor confidence in their potential but also signifies a strategic step towards expansive growth in their specialized fields.

Business keywords: Organ-on-a-Chip, 3D Human Disease Models, Predictive Toxicology, Microfluidics, Cell-based Assays, High-throughput Screening, Phenotypic Screening, Microphysiological Systems, Blood-brain Barrier Models, Liver Models, Kidney Models, 3D Cell Culture, Disease Modeling, Pharmaceutical Partnerships, Drug Development

Services & Products

CRO Services
Training
Product Development
AI/Automation
Disease Mechanism Understanding
Drug Efficacy and Safety Testing
Target Discovery and Validation
Compound Prioritization and Derisking

Target Customers

Pharmaceutical Companies Biotech Companies Academic Researchers Healthcare Researchers Regulatory Agencies

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Grant €3.01M 1
EASME - EU Executive Agency for SMEs
01 Jan 2019
Series B $20.50M 5
Aglaia Biomedical Ventures InnovationQuarter Oost NL
Aglaia Biomedical Ventures, InnovationQuarter +3
11 Apr 2018
Series B $1.60M -
05 Jan 2016
Series A $5.20M 2
PMV
PMV, Zeeuws Investerings Fonds
08 Oct 2014
Seed Round $1.60M -
11 Sep 2014

MIMETAS Alternatives & Competitors

View All Alternatives
MIMETAS vs
StemoniX
StemoniX United States

Pre-plated, human iPSC-derived microOrgans for toxicology and drug discovery research

Convertible Note
1 employees
Biotechnology, Health Care
Compare MIMETAS vs StemoniX
MIMETAS vs
CN Bio
CN Bio United Kingdom

Generate human-specific efficacy and safety data with PhysioMimix® microphysiological systems.

Series B
59 employees
Biopharma, Biotechnology
Compare MIMETAS vs CN Bio
MIMETAS vs
Emulate, Inc.
Emulate, Inc. United States

Our Organ-on-a-Chip technology provides a high-fidelity window into the inner workings of human biol...

Series F
71 employees
Biotechnology, Health Care
Compare MIMETAS vs Emulate, Inc.
View all alternatives

FAQ About MIMETAS

Human Tissue Models for Better Therapies
MIMETAS was founded in 2013.
MIMETAS is headquartered in The Netherlands.
MIMETAS operates in Biotechnology, Health Care, Information Technology and VR/AR. Its work centres on Organ-on-a-Chip, 3D Human Disease Models, Predictive Toxicology and Microfluidics. Its customers include Pharmaceutical Companies, Biotech Companies and Academic Researchers.
MIMETAS has a B2B, Platform and DaaS business model. Its revenue comes from Service Fee, Product Sales and Project Based.
MIMETAS has approximately 93 employees.
MIMETAS has completed 5 funding rounds, raising a total of $31.91M. The latest funding stage is Grant.
MIMETAS offers: CRO Services, Training, Product Development, AI/Automation, Disease Mechanism Understanding, Drug Efficacy and Safety Testing, Target Discovery and Validation, Compound Prioritization and Derisking.
Top alternatives and competitors to MIMETAS include StemoniX, CN Bio, Emulate, Inc., Paratus Sciences, Design Pharmaceuticals Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MIMETAS and StemoniX are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for MIMETAS, https://bouncewatch.com/company/mimetas, updated 24 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes